Expression and Function of the Alpha 7 Nicotinic Receptor in Schizophrenia
精神分裂症中α7烟碱受体的表达和功能
基本信息
- 批准号:8137492
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-01-01 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAmino Acid SequenceAutopsyBindingBinding SitesBrainBungarotoxinsCandidate Disease GeneCell LineChimera organismChromosomes, Human, Pair 3Cigarette SmokerCognitionCognitive deficitsComplexCoupledDataDeletion MutationDevelopmentDivalent CationsDominant-Negative MutationDrug Delivery SystemsExonsGene ExpressionGene StructureGeneral PopulationGenesGenetic TranscriptionGenotypeHippocampus (Brain)HumanInflammationLengthLigand BindingMammalian CellMeasuresMessenger RNAModelingMolecularMono-SNeuronsNicotineNicotine DependenceNicotinic ReceptorsNucleic Acid Regulatory SequencesOocytesPatientsPeptide Sequence DeterminationPeptidesPlayPrevalenceProcessProtein SubunitsProteinsReceptor GeneRegulationResearchRoleSchizophreniaSelf MedicationSmokeSmokerSmokingStreamStressStructureSurfaceSynapsesSystemTranscription Initiation SiteTranslatingTranslationsVeteransaddictionalpha Bungarotoxinchimeric genedensitydrug developmentduplicate geneshuman tissuein vivomRNA Expressionmutantneurotransmitter releasenon-smokerpromoterprotein expressionreceptorresearch studytissue culture
项目摘要
DESCRIPTION (provided by applicant):
The 17 neuronal nicotinic acetylcholine receptor gene (CHRNA7) is a replicated candidate gene for schizophrenia and is also protective in inflammation and stress. The protein subunit (17), derived from the gene, assembles with four other like subunits to form the pentameric, functional 17* receptor, which has five agonist-binding sites. The 17* receptor is an important target in drug development for cognitive deficits in schizophrenia. Agonist stimulation results in opening of the channel and entry of mono- and divalent cations, including Ca++, leading presynaptically to neurotransmitter release and postsynaptically to regulation at the post-synaptic density (PSD) and to down-stream changes in gene expression. Structure of CHRNA7, is complex; it is partially duplicated as a chimeric gene (CHRFAM7A). The chimera, CHRFAM7A, is expressed. Recent data suggests that CHRFAM7A acts as a dominant negative regulator of CHRNA7 binding and function. A 2bp deletion in CHRFAM7A is associated with schizophrenia and results in further decreasing CHRNA7 function. Schizophrenic patients have low levels of 17* receptors, as measured by binding of the ligand [125I]-1-bungarotoxin (I-BTX). Most of these patients are heavy cigarette smokers. The mRNA and protein in schizophrenic non-smokers is reduced compared to controls, but in the majority of subjects who smoke, there are normal levels of mRNA and protein. Thus, the low levels of I-BTX binding in schizophrenic patients are not explained by CHRNA7 mRNA or protein expression. We hypothesize that the duplicated gene, CHRFAM7A, acting as a dominant negative regulator, decreases the surface binding and function of 17* receptors. The current proposal will characterize the structure, expression and regulation of the CHRFAM7A gene and investigate its interaction with the full-length gene, CHRNA7.
PUBLIC HEALTH RELEVANCE:
The prevalence of schizophrenia is approximately 10% in Veterans, much higher than in the general population. Addiction, particularly to nicotine, is higher, ~35% in Veterans compared to 22% in the general population. Smoking and schizophrenia are intimately related since more than 80% of schizophrenics smoke, possibly as a form of self-medication. Nicotinic receptors are involved in both schizophrenia and smoking. The 17* nicotinic acetylcholine receptor, a replicated candidate gene in schizophrenia, is decreased in expression in schizophrenic brain and plays a role in nicotine addiction. A partial duplication of the receptor gene, CHRNA7, regulates its function. This proposal will characterize the partial duplication, CHRFAM7A, at the molecular level and study its expression in schizophrenia. The proposed research will contribute to development of additional 17* receptor-targeted drugs for cognition.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHERRY LEONARD其他文献
SHERRY LEONARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHERRY LEONARD', 18)}}的其他基金
Expression and Function of the Alpha 7 Nicotinic Receptor in Schizophrenia
精神分裂症中α7烟碱受体的表达和功能
- 批准号:
8255311 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Expression and Function of the Alpha 7 Nicotinic Receptor in Schizophrenia
精神分裂症中α7烟碱受体的表达和功能
- 批准号:
8398953 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Regulation of the Human a7 Nicotinic Receptor Gene in Schizophrenia
人类 a7 烟碱受体基因在精神分裂症中的调控
- 批准号:
7871065 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Regulation of the Human a7 Nicotinic Receptor Gene in Schizophrenia
人类 a7 烟碱受体基因在精神分裂症中的调控
- 批准号:
8063988 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Regulation of the Human a7 Nicotinic Receptor Gene in Schizophrenia
人类 a7 烟碱受体基因在精神分裂症中的调控
- 批准号:
7807156 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Regulation of the Human a7 Nicotinic Receptor Gene in Schizophrenia
人类 a7 烟碱受体基因在精神分裂症中的调控
- 批准号:
7301548 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Regulation of the Human a7 Nicotinic Receptor Gene in Schizophrenia
人类 a7 烟碱受体基因在精神分裂症中的调控
- 批准号:
7612655 - 财政年份:2007
- 资助金额:
-- - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
-- - 项目类别:














{{item.name}}会员




